HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 04, April 2018 – Digestive health in the 21st century - Trust your guts       » Food wasted in China could feed 30-50 million       » Chinese scientists analyze human brain's "CPU"       » $150,000 fundraiser launched to sequence South Asian genomes       » Green tea-based drug carriers improve cancer treatment       » Scientists grow liver cancer cells in lab      
BIOBOARD - AMERICAS
United States cancer drug costs increasing despite competition
New research study measured monthly price trajectories of 24 FDA cancer drugs and found mean cumulative cost increase was 37 percent, after a follow-up period of 12 years.

Anticancer drug costs in the United States increase substantially after launch regardless of competition, according to a new study published in the Journal of Clinical Oncology.

"This is the first study that systematically investigates oncology drug price changes with time and the correlation to the market structure," according to the researchers from Ben-Gurion University of the Negev (BGU), Rabin Medical Center and Tel Aviv University in Israel, as well as Emory University in Atlanta. "Our objective was to systematically measure the cost trajectories of individual anticancer drugs after their U.S. launch and to determine if price increases over time are anecdotal or a broader phenomenon."

The researchers measured the monthly price trajectories of 24 U.S. Food and Drug Administration-approved (FDA) cancer drugs and assessed the influence of market structure on price changes. To account for discounts and rebates, the research team used the average sales prices published by the Centers for Medicare and Medicaid Services and adjusted to general and health-related inflation rates. For each drug, the researchers calculated the cumulative and annual drug cost changes.

They found that after a follow-up period of 12 years, the mean cumulative cost increase was 37 percent, including all the injectable anticancer drugs. Annual changes in pricing did not appear to be affected by new supplemental FDA approvals, new off-label indications or new competition.

Notably, prices for leukemia drugs increased by 95 percent for arsenic trioxide/Trisenox and 85 percent for rituximab/Rituxan. Similar increases were found in trastuzumab/Herceptin for breast cancer, which jumped 78 percent.

"The only drug price that decreased with time was ziv-aflibercept/Zaltrap for metastatic colorectal cancer," the researchers note. "The drug was approved in 2012 and launched in the U.S. with a high and controversial price tag of more than $110,000 annually. After a public outcry led by Memorial Sloan Kettering Cancer Center in New York, manufacturer Sanofi immediately cut the price in half. By the end of the follow-up period in 2017, costs had decreased 13 percent.

"Regardless of competition or supplemental indications, our study found that there is a steady increase in costs of patented anticancer drugs over time," the researchers say. "We believe that new regulations may be needed to prevent additional increases in drug costs after launch especially since Medicare is legally prohibited from negotiating drug prices."

The research team included BGU鈥檚 Prof. Dan Greenberg and Noa Gordon, a Ph.D. candidate, BGU Department of Health Systems Management; Prof. Salomon Stemmer and Dr. Daniel Goldstein of The Davidoff Cancer Institute in the Rabin Medical Center, Petah-Tikvah; and Daniel A. Goldstein, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy